BANGKOK (Reuters) – Thailand will purchase an additional 12 million doses of Sinovac’s coronavirus vaccine to try to expedite its rollout, a senior official said on Tuesday, despite concerns over its efficacy against the Delta variant of COVID-19.
Thailand’s strategy had planned to use mainly locally produced AstraZeneca vaccines but with supply short of the government’s target, Sinovac shots are being used in a mix-and-match approach https://www.reuters.com/world/asia-pacific/thailand-starts-tighter-coronavirus-lockdown-around-capital-2021-07-12 to inoculate the population faster.
The mass vaccination campaign started in June but the rollout is being hastened by Thailand’s worst coronavirus wave so far, which is challenging Bangkok’s healthcare system at a time when just 7.3% of the population has been fully vaccinated.
Sinovac’s inactivated virus vaccine will be used as a first dose and AstraZeneca’s viral vector vaccine the second, a mix that officials say protects against the Delta variant.
Thailand was the first country to announce it would use this combination.
“A first shot of Sinovac follow by AstraZeneca significantly boosts immunity,” said Chawetsan Namwat, a senior health official at the Department of Disease Control.
Thailand reported a record 239 new COVID-19 deaths on Tuesday, with 7,973 fatalities overall, and is on course to pass the 1 million mark in cases this week.
It used the Sinovac vaccine initially for priority groups, medical personnel and the resort island of Phuket.
A Thai study carried out on medical personnel from May to July showed two doses of Sinovac offered 72% protection against infection and 98% protection against severe symptoms and death.
“The Sinovac vaccine that we used in Thailand is effective,” said Taweesap Sriprapasiri of the Department of Disease Control.
“Even with new variant, the vaccine is still effective.”
(Reporting by Chayut Setboonsarng, Panu Wongcha-um and Panarat Thepgumpanat; Editing by Martin Petty)
